Sarkomani davolash uchun mo'ljallangan terapiya
Saratonga begona emas, sarkoma haqida ko'p ma'lumot yo'q. Darhaqiqat, sarkoma ko'pincha odamlar tomonidan e'tiborga olinmaydigan saraton turidir. Ushbu turdagi saraton teri va periosteumda paydo bo'ladi va vaziyatning tez yomonlashishini aniqlashga to'liq mos keladi, sarkomaga qarshi dorilarning paydo bo'lishi bemorlarga nafas olish imkonini beradi, qisqa vaqt ichida kasallikni barqarorlashtirishi mumkin va keyin metastazning jiddiy holatini oldini olish, bemorlarning hayotiga xavf tug'dirish xavfini kamaytirish.
Sarkoma uchun maqsadli dori
Bevacizumab, pazopanib, sunitinib va boshqalar sarkomaga qarshi dorilardir, ammo bu har bir bemor uchun mos emas. Majburiy shart - genetik testni o'tkazish. Agar gen mutatsiyasi KRAS mutatsiyasi bo'lsa, MEK ingibitorlaridan, PIK3CA mutatsiyasi bo'lsa, BKM120, mTOR inhibitori va boshqalardan foydalanish mumkin. Agar u EGFR mutatsiyasi bo'lsa, TIKi preparatini qo'llash mumkin. Maqsadli dorilar hali ham g'oyalarga ega, ammo asosiysi genetik mutatsiya nima ekanligini aniq bilishdir, bu ikkinchi avlod sekvensiyasi texnologiyasining yordamini talab qiladi, chunki KRAS, PIK3CA, EGFR va METda genetik mutatsiyalar chastotasi 100% gacha qo'shilmaydi. . Agar shartlar imkon bersa, AVASTIN kimyoterapiya bilan birgalikda ishlatilishi mumkin.
Sarkomaga qarshi dorilar nima?
1.Bevasizumab
Bevacizumab, a human recombinant VEGF antibody, has been shown to have clinical efficacy in combination regimens in rectal cancer and other malignancies. Agulnik et al. Conducted a multi-center prospective, phase II clinical trial to evaluate the safety and effectiveness of the single-agent bevasizumab, including 30 patients with advanced STS, including 23 cases of angiosarcoma and 7 cases of epithelioid hemangioendothelioma. Monotherapy was well tolerated, partial response (PR), 2 cases, stable disease (SD), 15 cases. After two cycles of treatment, the median progression-free survival (PFS) was 12 weeks, and the overall survival (OS) was 52.7 weeks. This test shows that bevacizumab is safe and effective in patients with angiosarcoma and epithelioid hemangioendothelioma.
2. Pazopanib
Pazopanib og'iz orqali ko'p maqsadli kichik molekula retseptorlari tirozin kinaz inhibitori bo'lib, yumshoq to'qimalarning ilg'or sarkomasini (liposarkoma bo'lmagan) davolash uchun o'nlab yillar davomida FDA tomonidan tasdiqlangan birinchi maqsadli doridir. Pazopanib qon tomir endotelial o'sish faktorlari retseptorlari VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-a va -b, FGFR-1 va -3, sitokin retseptorlari (Kit), interleykin-2 retseptorlari A retseptorlari tirozin kinaz inhibitori T hujayra kinazini (Itk), leykotsitlarga xos protein tirozin kinazni (Lck) va transmembran glikoprotein retseptorlari tirozin kinazini (c-Fms) qo'zg'atishi mumkin. FDA rivojlangan sarkomasi bo'lgan bemorlar uchun pazopanibni tasdiqlaydi.
3.Sunitinib
Sunitinib is an oral small molecule receptor tyrosine kinase inhibitor with multiple effects of inhibiting shish angiogenesis and anti-tumor cell growth. Targets for the drug to exert anti-cancer effects include: PDGFR-α and -β, VEGFR1, VEGFR2, VEGFR3, FLT-3, CSF-1R, kit and ret. Sunitide has multiple effector pathways, making it a reliable anti-tumor targeted drug for non-GIST sarcomas, with two phase II clinical trials evaluating its safety and effectiveness.
4.Sorafinib
Sorafenib - og'iz orqali qabul qilinadigan multikinaz inhibitori. U bir vaqtning o'zida BRAF kinaz, VEGFR-2, VEGFR-3, PDGFR-b, KIT va FMSga o'xshash tirozin kinaz 3 (FLT-3) kabi turli xil hujayra ichidagi va hujayra yuzasi kinazlarini inhibe qilishi mumkin.
5. Cediranib
Sildenib, pan-tomir endotelial o'sish omili retseptorlari tirozin kinaz inhibitori, Kummar va boshqalar. II bosqich klinik tadqiqoti natijasida aniqlandiki, u metastatik asinar yumshoq to'qimalar sarkomasi uchun yaxshi samaradorlikni ko'rsatdi, 35% Bemorlar PRga erishdilar, SD bemorlarning 60% da sodir bo'ldi va 84 haftada umumiy kasallik nazorat qilish darajasi 24% ga etdi.
6. Anlotinib
Anlotinib ko'p maqsadli retseptorlari tirozin kinaz (RTK) inhibitori bo'lib, qon tomir endotelial o'sish omili retseptorlari (VEGFR1 / 2/3) va fibroblast o'sish omili retseptorlari (FGFR1 / 2/3) trombotsitlardan kelib chiqadigan o'sish omili retseptorlari (PDGFaRa) kabi maqsadlarga qaratilgan. / b), c-Kit va Ret. So'nggi yillarda uni o'simtaga qaratilgan terapiyada qo'llash bo'yicha tadqiqotlar davom etmoqda.
